Executive summary: US Patent 10,066,019 is a signal-peptide optimization patent aimed at recombinant antibody expression constructs. Its independent claim scope is broad at the antibody level (covers multiple approved therapeutic antibodies as selectable targets) but narrow at the construct-design level (limited to specific heavy-chain and light-chain signal peptide sequences and specific fusions to antibody heavy/light chain sequences). The enforceable “center of gravity” is likely the specific optimized signal peptide amino-acid sequences (listed as SEQ ID NOs) and the defined fusion architecture (C-terminal fusion of those signal peptides to antibody heavy/light chains, with specified N-/C-terminal boundaries on the light peptide). The risk to generic or biosimilar entrants is highest where they re-use the same expression signal peptides or replicate near-identical signal-peptide sequences and fusion junctions rather than swapping to different secretion signals or different signal-peptide variants.
US Patent 10,066,019 signal peptide landscape: what is claimed and what is protected?
What does US 10,066,019 claim at a high level?
The patent claims recombinant antibodies whose heavy and light chains are preceded by optimized signal peptides with defined amino-acid sequences and defined fusion endpoints:
- Heavy chain signal peptide: a C-terminal end is fused to the antibody heavy chain.
- Light chain signal peptide: an N-terminus is restricted to one of a small set of sequences, and a C-terminus is restricted to one of two sequences, with the light chain fused at the light peptide C-terminal end.
Core signal-peptide sequences expressly recited:
- Heavy chain signal peptides:
- SEQ ID NO: 5 (H1): MELGLSWIFLLAILKGVQC
- SEQ ID NO: 6 (H2): MELGLRWVFLVAILEGVQC
- SEQ ID NO: 1 (H5): MDWTWRFLFVVAAATGVQS
- SEQ ID NO: 9 (H6): MEFGLSWLFLVAILKGVQC
- SEQ ID NO: 3 (H7): MEFGLSWVFLVALFRGVQC
- Light chain signal peptide N-terminus options:
- SEQ ID NO: 311: MDMRVP
- SEQ ID NO: 312: MKYLLP
- Light chain signal peptide C-terminus options:
- SEQ ID NO: 313: SGARC
- SEQ ID NO: 314: QPAMA
Antibody targets expressly enumerated in the independent claim set (claim 1):
- trastuzumab, bevacizumab, infliximab, rituximab, adalimumab.
How is infringement likely structured: construct identity vs antibody biology?
This is primarily an expression/construct-architecture claim set:
- If the accused construct uses different signal peptides (different amino-acid sequences and/or different fusion junctions), it may fall outside the claim language even if the antibody is the same target therapeutic.
- If the accused construct uses the same signal peptide sequences and fusion endpoints, the biological function of the antibody is largely irrelevant to claim coverage.
Claim-by-claim scope mapping
- Claim 1 (independent):
Recombinant antibody selected from the listed therapeutics, with both heavy and light chains fused to specified signal peptide sequences, including the restricted light signal peptide N-terminus options.
- Claim 2:
Tightens light chain signal peptide C-terminal restriction (SGARC or QPAMA).
- Claims 3-7:
Pair specific heavy-chain signal peptide sequence(s) with specific antibodies (for claims 3-7, SEQ ID NO: 1 for trastuzumab, SEQ ID NO: 3 for bevacizumab/infliximab/rituximab/adalimumab).
- Claims 8-9:
Restricts light signal peptide to specific SEQ ID options (SEQ ID NO: 2 and then adalimumab specifically).
- Claims 10-12:
Polynucleotides encoding the signal peptide pairs and amino-acid sequences.
- Claims 11-16:
Product claims at the polypeptide level that combine:
- the full antibody heavy/light chain sequences (for the listed antibodies),
- plus the specific signal peptides at the defined junctions.
Critical reading: Claims 11, 13-16 effectively cover “the complete engineered amino-acid sequence” that includes signal peptides fused to the antibody chains, making it harder for an accused party to avoid by expressing the antibody but changing only part of the construct, as long as the full specified fusion architecture matches.
Which signal peptides (SEQ ID NOs) are the actual claim anchor for US 10,066,019?
Heavy chain signal peptide “anchor” sequences
For the explicitly mapped antibody embodiments in dependent claims:
- Trastuzumab embodiment: heavy signal peptide SEQ ID NO: 1 (H5): MDWTWRFLFVVAAATGVQS
- Bevacizumab / Infliximab / Rituximab / Adalimumab embodiments: heavy signal peptide SEQ ID NO: 3 (H7): MEFGLSWVFLVALFRGVQC
- Other heavy peptide options (SEQ ID NO: 5, 6, 9) remain within claim 1’s selectable heavy-chain signal peptide set, but are not tied in the text you provided to specific antibody mappings beyond claim 3-7.
Light chain signal peptide “anchor” sequences
Claim 1 and claim 2 constrain both ends of the light signal peptide:
- N-terminus options: MDMRVP (SEQ ID NO: 311) or MKYLLP (SEQ ID NO: 312)
- C-terminus options: SGARC (SEQ ID NO: 313) or QPAMA (SEQ ID NO: 314)
The patent also includes embodiments where the light signal peptide is referenced as SEQ ID NO: 2 (claim 8-9). If SEQ ID NO: 2 corresponds to a specific assembled light signal peptide sequence (not just “MDMRVP + … + SGARC/QPAMA”), it becomes a direct binary test for infringement: does the accused construct use that exact sequence?
Fusion architecture matters
The claims repeatedly require:
- C-terminal end of the heavy chain signal peptide fused to the heavy chain.
- N-terminus of the light chain signal peptide comprises one of the listed short sequences.
- C-terminus of the light chain signal peptide comprises SGARC or QPAMA (and then fused to the light chain).
Even if a signal peptide has high similarity, different cleavage site architecture or different junction residues can change literal infringement risk.
How strong is the patent estate for US 10,066,019 against biosimilars and generic antibodies?
Strength drivers
- Specific amino-acid sequence recitation.
Literal scope hinges on exact sequences listed as SEQ ID NOs, which can be comparatively easier to enforce than “functional” expression claims.
- Complete engineered polypeptide claims (claims 11, 13-16).
These can capture constructs where the entire fusion sequence is used in manufacturing.
Strength limitations
- Claim 1’s antibody list narrows targets but still covers major commercial antibodies.
If an accused biosimilar covers a different antibody, US 10,066,019 may not apply because claim 1 explicitly enumerates those antibody targets.
- Design-around availability at signal peptide level.
Parties can often switch secretion signal peptides or modify signal-peptide variants (while maintaining product comparability), which can avoid literal infringement if the new signal peptides are not in the claimed set.
- Expression systems and cleavage differences.
If an accused party uses the same antibody heavy/light sequences but uses different signal peptides or different fusion junctions, the constructs may fall outside.
Competitive implication
US 10,066,019 is most relevant to:
- biosimilar entrants that express the enumerated antibodies using constructs based on the same signal peptides.
- any “follow-on” engineered antibody products that reuse those exact signal-peptide sequences.
What patents could be adjacent or competing around US 10,066,019?
This prompt provides only the claims of US 10,066,019, not its specification, priority chain, family members, or cited references. Without those, a complete landscape (related patents, family members, or prosecution history) cannot be built without risking factual errors. Per constraints, no additional assertions are made.
What is the likely claim construction and litigation posture for signal-peptide fusion claims?
Key claim terms likely to be litigated
- “optimized heavy chain signal peptide and light chain signal peptide”
- “C-terminal end … fused to a heavy chain/light chain”
- exact sequence matching to the listed SEQ ID NO amino-acid strings
- whether the claimed light signal peptide includes specific termini (and whether shorter listed N-termini are sufficient when combined with the rest of the signal peptide)
Infringement theory most likely used
- Literal infringement: Compare the accused construct sequences to the claimed SEQ ID strings and junctions.
- Construction/accuracy: Identify the secretion signal sequence used in the expression plasmid (or integrated vector), then map the exact cleavage/junction boundary and resulting translated fusion product.
- Direct product infringement: If the patent includes polynucleotide and amino-acid fusion claims, proving the sequence used in manufacturing can be dispositive.
Design-around likely defenses
- Use an unclaimed signal peptide for either heavy or light chain.
- Use the same general architecture but swap at least one residue so that the resulting signal peptide is no longer identical to the claimed sequence.
- Change the fusion junction such that the signal peptide no longer terminates with the required C-terminal residues.
Where do the claims point to specific antibodies: coverage matrix
Embodiment mapping extracted from your claim text
| Antibody target |
Claimed heavy-chain signal peptide |
Claimed light-chain signal peptide (as constrained in the claims you provided) |
Where appears in claims |
| Trastuzumab |
SEQ ID NO: 1 (H5) = MDWTWRFLFVVAAATGVQS |
Light fusion includes SEQ ID NO: 2 (claim 11 references SEQ ID NO: 2; claim 1 also allows N-terminus MDMRVP or MKYLLP) |
Claim 3; Claim 11 |
| Bevacizumab |
SEQ ID NO: 3 (H7) = MEFGLSWVFLVALFRGVQC |
Light fusion includes SEQ ID NO: 2 |
Claim 4; Claim 13 |
| Infliximab |
SEQ ID NO: 3 (H7) |
Light fusion includes SEQ ID NO: 4 |
Claim 5; Claim 14 |
| Rituximab |
SEQ ID NO: 3 (H7) |
Light fusion includes SEQ ID NO: 4 |
Claim 6; Claim 15 |
| Adalimumab |
SEQ ID NO: 3 (H7) |
Light fusion includes SEQ ID NO: 2 |
Claim 7; Claim 16 |
Light-chain detail from claim 2
Regardless of the SEQ ID NO: 2 vs 4 references, claim 2 requires the light signal peptide C-terminus be SGARC (SEQ ID NO: 313) or QPAMA (SEQ ID NO: 314). That can become a secondary, sequence-level check on any accused construct.
When does US 10,066,019 lose exclusivity and what FDA exclusivity overlaps?
No filing dates, priority dates, patent term adjustment, or FDA listing details are provided in the prompt. Without those, any exclusivity timeline would be speculative.
What is the Orange Book status of US 10,066,019?
This patent appears to relate to antibody constructs that are typically regulated as biologics under the BPCIA and listed in the Biologics License Application (BLA) context, not the Orange Book for drugs. However, no FDA list data is included here, so no definitive Orange Book status can be stated.
How many patents cover these antibody signal peptides and what geographic coverage applies?
No family data, co-pending continuations, or foreign filings are provided. A numeric count of overlapping patents and their geographic reach cannot be completed without introducing unsupported facts.
What generic entry risks exist for the enumerated antibodies from a signal-peptide IP perspective?
Because antibodies are generally not “generics” in the Orange Book sense, the entry risk is framed as biosimilar/biologic follow-on risk. From an IP standpoint, the risk is:
- High if the entrant uses identical heavy/light signal peptide sequences and fusion junctions that map to the claimed SEQ ID NOs.
- Medium to low if the entrant can substitute a different secretion signal peptide sequence and/or revise fusion junction residues while preserving antibody quality attributes.
The patent’s enforceability is therefore tied less to the antibody target and more to the manufacturing construct sequence choices.
Key Takeaways
- US 10,066,019 is a sequence-defined signal-peptide fusion patent covering recombinant forms of major therapeutic antibodies named in the claims.
- The enforceable core is exact amino-acid sequence identity for the heavy-chain and light-chain signal peptides (SEQ ID NOs) and the required fusion architecture to the antibody heavy/light chains.
- Claim breadth is constrained by enumerated antibody targets and exact sequence limits, creating a plausible design-around path by changing signal peptides or junctions.
- Likely litigation hinges on construct sequence mapping and junction residency rather than antibody pharmacology.
FAQs
-
Does US 10,066,019 cover an antibody if the target antigen is the same but the signal peptide sequence differs?
Only if the accused heavy and light chain secretion signal peptides and fusion junctions match the claimed sequences and architecture.
-
Can a biosimilar avoid US 10,066,019 by switching heavy-chain signal peptides but keeping the light-chain signal peptide?
Avoidance is plausible if either chain’s signal peptide is not identical to the claimed SEQ ID NOs and junction requirements.
-
What parts of the light-chain signal peptide are most critical under the claims?
The light signal peptide N-terminus selection (MDMRVP or MKYLLP) and the C-terminal residue set (SGARC or QPAMA), plus the fusion to the light chain.
-
Are the polynucleotide claims a stronger enforcement tool than the antibody claims?
Sequence-based polynucleotide claims can be powerful if manufacturing plasmid/vector sequences are established, but their practical strength depends on proof access in litigation.
-
Do the claims protect expression methods or only the engineered antibody sequences?
Based on the claim text provided, the protection centers on the engineered signal peptide and fused sequences (and encoding polynucleotides), not on process steps.
References
- US Patent 10,066,019 (claims text provided in user prompt).
